ABVC BioPharma Receives $150K Milestone From AiBtl, Bringing Total Licensing Revenue to $846K Across Strategic Partnerships
SILICON VALLEY, CA - July 10, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ('Company'), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today announced that it has received a $150,000 cash licensing payment from AiBtl BioPharma Inc., one of its key strategic partners, as part of a broader licensing agreement signed earlier this year.
The payment marks a significant milestone in the continuing commercialization of ABVC's late-stage drug candidates ABV-1504 and ABV-1505, which are being developed for Major Depressive Disorder (MDD) and Attention Deficit Hyperactivity Disorder (ADHD) respectively. Both candidates have completed Phase II and Phase IIB clinical trials and hold active INDs with the U.S. Food and Drug Administration.
'This milestone payment reflects the accelerating momentum behind our global licensing strategy and validates the value of our late-stage clinical assets,' said Dr. Uttam Patil, ABVC Chief Executive Officer. 'Our partnership with AiBtl exemplifies how we are strategically collaborating with innovation-focused companies to bring our botanical therapies to market worldwide.'
Cumulative Licensing Milestone
To date, AiBtl BioPharma has paid a total of $350,000 in cash milestone licensing fees to ABVC. Including earlier payments from other strategic partners such as ForSeeCon and OncoX, ABVC has received a cumulative total of $846,000 in non-dilutive licensing income. These milestone payments reflect growing interest in ABVC's late-stage botanical drug portfolio and reinforce the Company's capital-efficient, partnership-driven business model.
Strengthening a Global Platform for Botanical Innovation
Over the past six months, ABVC has successfully executed licensing agreements with multiple partners across North America and Asia, including:
AiBtl BioPharma Inc. - Licensed ABV-1504 and ABV-1505 for global development and commercialization, for which ABVC will receive equity, cash milestone payments, and royalties. ABVC and its subsidiary BioLite Inc. received 46M AiBtl shares, and are eligible for potential $7M cash payment, and royalties up to $200M after the product launches.
ForSeeCon Eye Corporation - Secured a license for ophthalmic indications under ABVC's botanical IP platform. ABVC and its subsidiaries BioFirst Corporation have received 10M ForSeeCon shares, and are eligible for potential $7M cash payment, and royalties up to $120M after the product launches.
OncoX BioPharma, Inc. - Entered into a deal to expand botanical innovation into the oncology space. ABVC and its subsidiaries BioLite Inc. and Rgene Corporation are received up to 10M OncoX shares, and are eligible for potential $5M cash payment, and royalties up to $50M after the product launches.
These deals are aligned with ABVC's asset-light business model, focusing on developing innovative botanical drugs through Phase II/III, and licensing out clinical-stage products to commercial partners for global expansion.
Outlook and Commitment to Shareholder Value
This $150,000 payment is part of a larger milestone and royalty structure that is expected to contribute significantly to ABVC's 2025 revenue stream. The company previously announced a 234% increase in annual revenue and a 77% year-over-year improvement in earnings per share, reflecting its capital-efficient approach and licensing-driven growth. These improvements reflect ABVC's pivot toward a licensing-first strategy, which is designed to generate recurring milestone income and reduce the need for dilutive fundraising.
'Our licensing-first strategy is working, and today's payment is one of several anticipated milestone payments as partners progress clinical development activities under our licensing agreements,' added Dr. Patil. 'We remain committed to creating sustainable long-term value for our shareholders through focused innovation, smart partnerships, and disciplined execution.'
Addressing a Global Need for CNS Therapies
The growing demand for alternative and effective treatments for CNS disorders has become more urgent globally. According to The Daily Telegraph (July 7, 2025), Australia is currently facing a serious drug shortage, with nearly 300,000 patients expected to be affected, potentially driving some to seek medication through illegal channels. ABVC and AiBtl's progress in botanical drug development could offer a timely and legal therapeutic alternative to vulnerable patient populations in need. [1]
[1]https://ttmgoal.com/news/2549374126?edition=fundamental&utm_source=news&utm_campaign=2549374126&utm_medium=telegram&platform=iOS&shareID=fd3ffdab45abd814bfccde5ecba5541b&invite=P2VN3E⟨=en_US
About AiBtl BioPharma Inc.
AiBtl BioPharma Inc. is a Delaware-based biopharmaceutical company focused on the development of botanical-based therapeutic candidates for central nervous system (CNS) disorders, including major depressive disorder (MDD) and attention deficit hyperactivity disorder (ADHD). Leveraging a combination of traditional botanical knowledge and modern clinical research, AiBtl seeks to advance drug candidates derived from Polygala tenuifolia, a traditional medicinal herb. AiBtl operates with a strategic focus on Asia-Pacific markets and is exploring collaborative opportunities with global pharmaceutical partners to support late-stage development and commercialization. ABVC BioPharma currently holds a majority ownership stake in AiBtl.
About ABVC BioPharma & Its Industry
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus(R)) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus(R), the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships.
Forward-Looking Statements
This press release contains 'forward-looking statements.' Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential,' or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
Contact:
Uttam Patil
Email: [email protected]
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
3 Dividend Stocks to Hold for the Next 20 Years
Key Points General Mills is offering a historically high yield backed by a powerful and diversified food business. PepsiCo is a Dividend King with a high yield and iconic global brands. Hershey makes an affordable luxury that people will be willing to pay up for. 10 stocks we like better than PepsiCo › Remember one thing when you consider consumer staples makers: You "need" the products they sell. That's particularly true when it comes to food-focused consumer staples companies like General Mills (NYSE: GIS), PepsiCo (NASDAQ: PEP), and Hershey (NYSE: HSY). Here's why each one of these dividend stocks is worth buying and holding for 20 years, or more, right now. 1. General Mills is shifting with the times General Mills makes food products like cereal, snack bars, pet food, and baking products. It owns a collection of brand names that you likely know well, including Blue Buffalo and Cheerios. The brands and products it sells are staples in grocery stores and in consumer cupboards. It's highly unlikely that General Mills will suddenly go out of business anytime soon. That said, right now the company is facing some headwinds. Consumer buying habits are shifting, and some buyers are pulling back on spending. That has left General Mills' financial results weak. Sales and earnings fell year over year in the fourth quarter of fiscal 2025. The company's fiscal 2026 outlook was a bit weak, too. But management is doing what it can to adjust, including changing formulations to match current trends, adjusting its brand and product portfolio, and trying to keep a lid on costs. These are the right moves and, in time, they will likely lead to General Mills getting back on track. It always has in the past. While General Mills' stock is out of favor, you can buy it at an attractive 4.8% yield. That's near the highest levels in the company's history. If you like income and think long term, General Mills should probably be on your buy list today. 2. PepsiCo has industry-leading brands General Mills is a good company with industry-leading brands, but PepsiCo's brands stand out even more. It's the No. 2 beverage company and the No. 1 salty snack maker. It also makes packaged food products that compete with companies like General Mills. The problem for PepsiCo is that customer tastes are shifting, and it is out of step with its customers. The company is working on the issue -- it recently bought a Mexican-American food business and a probiotic beverage company. Both are more in line with current trends. Sure, PepsiCo's recent financial results aren't that great, and they lag those of its closest peers. It's OK -- that happens even to well-run businesses. PepsiCo didn't achieve Dividend King status by accident, and it has muddled through hard times before. It's highly likely that it will do so again. In the meantime, you can collect a historically high 3.9% dividend yield. If the dividend history here is any guide, you'll end up a long-term winner if you're willing to step in while the rest of Wall Street is selling. 3. Hershey's cocoa problem makes it hard to love Hershey is the most difficult story to appreciate here for two reasons. First, while it makes food, the most important product it sells is chocolate. That's not a necessity, even though people love the affordable indulgence. Second, the biggest headwind for the business is a shocking rise in the price of cocoa, a key ingredient in chocolate. Cocoa comes from trees, so it could take some time before high prices lead to changes in the industry. That's why investors have sold Hershey stock hard, leading to a historically high 2.9% dividend yield. Just how bad is it? Despite increasing prices and the expectation of sales growth in 2025, Hershey is projecting rising costs to lead to a roughly mid-30% drop in earnings in 2025. And given the nature of cocoa, the pain could linger for a bit. There's a good reason why investors are negative on the stock. But if you can stomach some near-term uncertainty, the long-term picture is likely to be continued and growing demand for the affordable luxuries that Hershey sells. You need and want what they make It is hard to suggest that chocolate, soda, or cereal are life necessities. You can certainly eat and drink other things. But these consumer staples giants have long delivered the food items that people want to buy. That will be just as true in one year as it is in 10 years or 20 years. The headwinds they face today aren't likely to change anything about the nature of these businesses, even if the companies do need to adjust to better align with current trends. The truth is that they've all done that many times before. Given the historically high yields on offer from General Mills, PepsiCo, and Hershey, buying and holding for decades is probably a good call for even the most conservative dividend investors today. Do the experts think PepsiCo is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did PepsiCo make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,036% vs. just 181% for the S&P — that is beating the market by 855.09%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Reuben Gregg Brewer has positions in General Mills, Hershey, and PepsiCo. The Motley Fool has positions in and recommends Hershey. The Motley Fool has a disclosure policy. 3 Dividend Stocks to Hold for the Next 20 Years was originally published by The Motley Fool
Yahoo
18 minutes ago
- Yahoo
This Surprising Pizza Stock Is Beating the Market in 2025. Time to Buy?
Key Points Domino's Pizza stock is up 7,800% since its IPO in 2004. Most of its current growth comes from adding locations. Its 28 P/E ratio could discourage more buying at current growth rates. 10 stocks we like better than Domino's Pizza › Domino's Pizza (NASDAQ: DPZ) has attracted some unexpected attention in recent years. Its stock has traded since 2004, and despite the highly competitive nature of the pizza industry, it has returned more than 7,800% between a rising stock price and dividend payments. Amid that growth, Domino's has beaten the market in 2025. Moreover, Warren Buffett's company, Berkshire Hathaway, has increased its share holdings in every quarter since the third quarter of 2024. Do those moves mean investors should follow Buffett's team into this pizza stock? Let's take a closer look. Domino's growing popularity Domino's has long stood out in the pizza business for its franchises, which delivered pizza decades before delivery services like DoorDash became commonplace. Despite such emerging competitors, Domino's remains the world's largest pizza delivery company. Additionally, it has switched to a primarily digital platform, which drove more than 85% of sales in 2024. Even as it adapts that business model, Domino's operates more than 21,500 locations across 90 countries. It derives revenue from franchise fees, royalties, its in-house supply chain, and company-run stores in the U.S. Although the supply chain and company-run stores generate the majority of the company's revenues, the high costs associated with these businesses mean that franchise fees and royalties likely account for the majority of the company's profits. This emphasis on such higher-margin enterprises may have attracted Buffett's team to this stock. Nonetheless, it is also worth asking whether Domino's will continue to beat the market in the current environment. What the company's numbers show Investors are likely to have mixed reactions to Domino's results and financial condition. In the second quarter of fiscal 2025 (ended June 15), its revenue rose to more than $1.1 billion, a 4% increase from year-ago levels. The fact that store additions accounted for most of its revenue growth may disappoint Domino's stock bulls. As mentioned earlier, the company operates approximately 21,500 locations worldwide. That rose by 600 locations or 3% over the last year, a rate that nearly matches the overall revenue growth. During Q2, Domino's reported higher operating profits, but $16 million in unrealized losses weighed on the bottom line. Consequently, Domino's reported $131 million in net income, an 8% drop from year-ago levels. However, the financials offered some good news, and one factor that could have attracted Berkshire's interest is the improvement in free cash flow. In the first half of fiscal 2025, free cash flow was $332 million compared to $231 million in the same quarter last year. Berkshire may have also bought Domino's because of its dividend growth. Its annual payout of $6.96 per share amounts to a dividend yield of about 1.5%, not far above the 1.2% average for the S&P 500. Still, Domino's raised its dividend by 15% earlier this year, the 12th consecutive annual increase for the company. Such an increase and the continuing streak of payout hikes is an explicit vote of confidence for its ability to drive returns for shareholders. The question for investors is whether the dividend bolsters enough confidence to justify its valuation. At a P/E ratio of 28, Domino's is slightly cheaper than its five-year average earnings multiple of 30. Still, that is likely not low enough to attract value investors, a factor that may not bode well for the stock's continued growth. Is it time to buy Domino's Pizza stock? Given the current state of Domino's and its financials, the stock is likely a hold at current levels. Admittedly, that may differ from Berkshire's view, as it added shares over the three prior quarters. Moreover, the store additions serve as a tailwind, and the overall history of Domino's stock points to outsized returns to its investors. Nonetheless, Domino's is not a cheap stock at 28 times earnings. Additionally, most of its revenue growth came from store additions, and its dividend yield is only slightly above S&P 500 averages. Such returns should serve longtime shareholders well, but they offer little motivation to buy additional shares or choose Domino's over the indexes. Thus, investors should probably keep Domino's on a watch list rather than adding shares at this time. Should you invest $1,000 in Domino's Pizza right now? Before you buy stock in Domino's Pizza, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Domino's Pizza wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Will Healy has positions in Berkshire Hathaway. The Motley Fool has positions in and recommends Berkshire Hathaway, Domino's Pizza, and DoorDash. The Motley Fool has a disclosure policy. This Surprising Pizza Stock Is Beating the Market in 2025. Time to Buy? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Upstart Holdings, Inc. (UPST) Suffers a Larger Drop Than the General Market: Key Insights
Upstart Holdings, Inc. (UPST) closed the most recent trading day at $79.22, moving -3.08% from the previous trading session. This change lagged the S&P 500's daily loss of 1.6%. On the other hand, the Dow registered a loss of 1.23%, and the technology-centric Nasdaq decreased by 2.24%. Shares of the company have appreciated by 10.73% over the course of the past month, outperforming the Finance sector's gain of 0.8%, and the S&P 500's gain of 2.25%. Investors will be eagerly watching for the performance of Upstart Holdings, Inc. in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 5, 2025. The company is expected to report EPS of $0.27, up 258.82% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $225.3 million, indicating a 76.52% growth compared to the corresponding quarter of the prior year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $1.58 per share and a revenue of $1.02 billion, representing changes of +890% and +59.46%, respectively, from the prior year. Investors might also notice recent changes to analyst estimates for Upstart Holdings, Inc. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. At present, Upstart Holdings, Inc. boasts a Zacks Rank of #3 (Hold). In terms of valuation, Upstart Holdings, Inc. is presently being traded at a Forward P/E ratio of 51.8. This expresses a premium compared to the average Forward P/E of 12.03 of its industry. The Financial - Miscellaneous Services industry is part of the Finance sector. At present, this industry carries a Zacks Industry Rank of 70, placing it within the top 29% of over 250 industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Upstart Holdings, Inc. (UPST) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
